Atara Biotherapeutics (ATRA)
(Delayed Data from NSDQ)
$0.69 USD
-0.01 (-1.40%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $0.69 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth C Momentum F VGM
Atara Biotherapeutics (ATRA) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$3.44 | $13.00 | $0.40 | 391.43% |
Price Target
Based on short-term price targets offered by five analysts, the average price target for Atara Biotherapeutics comes to $3.44. The forecasts range from a low of $0.40 to a high of $13.00. The average price target represents an increase of 391.43% from the last closing price of $0.70.
Analyst Price Targets (5 )
Broker Rating
Atara Biotherapeutics currently has an average brokerage recommendation (ABR) of 3.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by eight brokerage firms. The current ABR compares to an ABR of 3.00 a month ago based on eight recommendations.
Of the eight recommendations deriving the current ABR, two are Strong Buy, representing 25% of all recommendations. A month ago, Strong Buy represented 25%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 2 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 4 | 4 | 4 | 4 | 4 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 2 | 2 | 2 | 2 | 2 |
ABR | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/28/2024 | Canaccord Genuity | John L Newman | Strong Buy | Strong Buy |
3/1/2024 | H.C. Wainwright & Co. | Robert Burns | Hold | Hold |
11/9/2023 | Evercore Partners | Jonathan Miller | Not Available | Hold |
11/9/2023 | Mizuho SecuritiesUSA | Salim Syed | Not Available | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 3.00 |
ABR (Last week) | 3.00 |
# of Recs in ABR | 8 |
Average Target Price | $3.44 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 75 of 252 |
Current Quarter EPS Est: | -0.37 |